{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:56:05Z","timestamp":1792526165191,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1341,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1124\/jpet.120.000348","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T19:15:21Z","timestamp":1614626121000},"page":"218-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["An Integrative Approach for Improved Assessment of Cardiovascular Safety Data"],"prefix":"10.1016","volume":"377","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-736X","authenticated-orcid":false,"given":"Mikael","family":"Wallman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Scheuerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pairet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jirstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gabrielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000348_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2125.2000.00243.x","article-title":"The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing","volume":"50","author":"Allen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0378-4347(93)80232-S","article-title":"Simultaneous determination of the enantiomers of pimobendan and its main metabolite in rat plasma by high-performance liquid chromatography","volume":"614","author":"Asakura","year":"1993","journal-title":"J Chromatogr A"},{"key":"10.1124\/jpet.120.000348_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/00498254.2011.604746","article-title":"Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats","volume":"42","author":"Bertera","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.120.000348_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0022-3565(24)37128-9","article-title":"Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat","volume":"283","author":"Bol","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000348_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0090-9556(24)15308-1","article-title":"Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects","volume":"27","author":"Chu","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000348_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0009-9236(95)90223-6","article-title":"Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing","volume":"57","author":"Chu","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.120.000348_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00045391-199811000-00010","article-title":"Mechanisms offsetting the beneficial effects of antihypertensive drugs: a problem increasingly considered but incompletely understood","volume":"5","author":"Cleophas","year":"1998","journal-title":"Am J Ther"},{"key":"10.1124\/jpet.120.000348_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The comprehensive in vitro proarrhythmia assay (CiPA) initiative - update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.120.000348_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fnins.2017.00461","article-title":"Resetting of the baroreflex control of sympathetic vasomotor activity during natural behaviors: description and conceptual model of central mechanisms","volume":"11","author":"Dampney","year":"2017","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.120.000348_bib10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s40265-013-0117-0","article-title":"Selective and specific inhibition of if with ivabradine for the treatment of coronary artery disease or heart failure","volume":"73","author":"Deedwania","year":"2013","journal-title":"Drugs"},{"key":"10.1124\/jpet.120.000348_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.bjp.0705696","article-title":"I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities","volume":"142","author":"Du","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0928-0987(00)00086-5","article-title":"A pharmacokinetic simulation model for ivabradine in healthy volunteers","volume":"10","author":"Duffull","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/jpet.120.000348_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0090-9556(25)06622-X","article-title":"An improved pharmacodynamic model for formation of methemoglobin by antimalarial drugs","volume":"23","author":"Fasanmade","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000348_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF01059111","article-title":"A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers","volume":"21","author":"Francheteau","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.120.000348_bib15","series-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications","author":"Gabrielsson","year":"2016"},{"key":"10.1124\/jpet.120.000348_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.120.000348_bib17","doi-asserted-by":"crossref","first-page":"e00270","DOI":"10.1002\/prp2.270","article-title":"Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation","volume":"4","author":"Gotta","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/jpet.120.000348_bib18","first-page":"435","article-title":"Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature","volume":"7","author":"Gresser","year":"2002","journal-title":"Eur J Med Res"},{"key":"10.1124\/jpet.120.000348_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev.ph.34.030172.000305","article-title":"Circulation: overall regulation","volume":"34","author":"Guyton","year":"1972","journal-title":"Annu Rev Physiol"},{"key":"10.1124\/jpet.120.000348_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1745-7254.2007.00556.x","article-title":"Pharmacokinetic-pharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats","volume":"28","author":"Hao","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/jpet.120.000348_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vascn.2013.05.004","article-title":"Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium","volume":"69","author":"Holzgrefe","year":"2014","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.120.000348_bib22","series-title":"Cross-species Scaling of Cardiovascular Safety Pharmacology Using PKPD Modelling and Simulation","author":"Howgate","year":"2013"},{"key":"10.1124\/jpet.120.000348_bib23","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/bph.13561","article-title":"Quantitative pharmacokinetic-pharmacodynamic modelling of baclofen-mediated cardiovascular effects using BP and heart rate in rats","volume":"173","author":"Kamendi","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/BF00161201","article-title":"A mathematical model for fundamental regulation processes in the cardiovascular system","volume":"31","author":"Kappel","year":"1993","journal-title":"J Math Biol"},{"key":"10.1124\/jpet.120.000348_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.yrtph.2016.01.003","article-title":"Pharmacokinetic-pharmacodynamic analyses of antihypertensive drugs, nifedipine and propranolol, in spontaneously hypertensive rats to investigate characteristics of effect and side effects","volume":"76","author":"Kiriyama","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-3565(25)24622-5","article-title":"Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent","volume":"244","author":"Kitzen","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000348_bib27","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.120.000348_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1152\/physiolgenomics.00164.2002","article-title":"Evaluation and applications of radiotelemetry in small laboratory animals","volume":"13","author":"Kramer","year":"2003","journal-title":"Physiol Genomics"},{"key":"10.1124\/jpet.120.000348_bib29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/01.CIR.85.3.942","article-title":"Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial","volume":"85","author":"Kubo","year":"1992","journal-title":"Circulation"},{"key":"10.1124\/jpet.120.000348_bib30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csda.2004.07.002","article-title":"Maximum likelihood estimation in nonlinear mixed effects models","volume":"49","author":"Kuhn","year":"2005","journal-title":"Comput Stat Data Anal"},{"key":"10.1124\/jpet.120.000348_bib31","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.46.3.938-939.2002","article-title":"Importance of species selection in arrythmogenic models of Q-T interval prolongation","volume":"46","author":"McDermott","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.120.000348_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.ijir.3901522","article-title":"The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy","volume":"19","author":"Mehrotra","year":"2007","journal-title":"Int J Impot Res"},{"key":"10.1124\/jpet.120.000348_bib33","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/01.CIR.102.21.2665","article-title":"Cardiovascular drugs. Dofetilide","volume":"102","author":"Mounsey","year":"2000","journal-title":"Circulation"},{"key":"10.1124\/jpet.120.000348_bib34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3389\/fphys.2018.00897","article-title":"Unanesthetized rodents demonstrate insensitivity of QT interval and ventricular refractory period to pacing cycle length","volume":"9","author":"Mulla","year":"2018","journal-title":"Front Physiol"},{"key":"10.1124\/jpet.120.000348_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1113\/jphysiol.1962.sp006849","article-title":"A modification of the Hodgkin--Huxley equations applicable to Purkinje fibre action and pace-maker potentials","volume":"160","author":"Noble","year":"1962","journal-title":"J Physiol"},{"key":"10.1124\/jpet.120.000348_bib36","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1128\/AAC.44.10.2630-2637.2000","article-title":"Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats","volume":"44","author":"Ohtani","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.120.000348_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ahj.2009.06.007","article-title":"Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative","volume":"158","author":"Piccini","year":"2009","journal-title":"Am Heart J"},{"key":"10.1124\/jpet.120.000348_bib38","first-page":"H2000","article-title":"Rapid resetting of carotid baroreceptor reflex by afferent input from skeletal muscle receptors","volume":"275","author":"Potts","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.120.000348_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0163-7258(95)02063-2","article-title":"Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias?","volume":"69","author":"Rees","year":"1996","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.120.000348_bib40","doi-asserted-by":"crossref","first-page":"25388","DOI":"10.1038\/srep25388","article-title":"The complex QT\/RR relationship in mice","volume":"6","author":"Roussel","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.120.000348_bib41","doi-asserted-by":"crossref","first-page":"1510821","DOI":"10.1080\/2331205X.2018.1510821","article-title":"Oral bioavailability and pharmacokinetics of sildenafil citrate dry foam tablets in rats","volume":"5","author":"Sawatdee","year":"2018","journal-title":"Cogent Med"},{"key":"10.1124\/jpet.120.000348_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1056-8719(00)00101-5","article-title":"Continuous assessment of multiple vital physiological functions in conscious freely moving rats using telemetry and a plethysmography system","volume":"43","author":"Schierok","year":"2000","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.120.000348_bib43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/00498259209053133","article-title":"Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man","volume":"22","author":"Smith","year":"1992","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.120.000348_bib44","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1111\/bph.12824","article-title":"Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling","volume":"171","author":"Snelder","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.120.000348_bib_","doi-asserted-by":"crossref","first-page":"H1573","DOI":"10.1152\/ajpheart.00794.2003","article-title":"A model for human ventricular tissue","volume":"286","author":"ten Tusscher","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.120.000348_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1126\/science.7604285","article-title":"HERG, a human inward rectifier in the voltage-gated potassium channel family","volume":"269","author":"Trudeau","year":"1995","journal-title":"Science"},{"key":"10.1124\/jpet.120.000348_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2210-5-5","article-title":"Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs - method development and application to magnesium in sheep","volume":"5","author":"Upton","year":"2005","journal-title":"BMC Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib48","doi-asserted-by":"crossref","first-page":"H1479","DOI":"10.1152\/ajpheart.00850.2002","article-title":"Role of short-term cardiovascular regulation in heart period variability: a modeling study","volume":"284","author":"Ursino","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.120.000348_bib49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.bjp.0707234","article-title":"Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint","volume":"151","author":"van Steeg","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0090-4295(02)01510-8","article-title":"Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men","volume":"59","author":"Vardi","year":"2002","journal-title":"Urology"},{"key":"10.1124\/jpet.120.000348_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.RES.84.5.571","article-title":"Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies","volume":"84","author":"Winslow","year":"1999","journal-title":"Circ Res"},{"key":"10.1124\/jpet.120.000348_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/01.RES.80.2.261","article-title":"Tissue and species distribution of mRNA for the IKr-like K+ channel, erg","volume":"80","author":"Wymore","year":"1997","journal-title":"Circ Res"},{"key":"10.1124\/jpet.120.000348_bib53","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1476-5381.2012.02200.x","article-title":"Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials","volume":"168","author":"Zemzemi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000348_bib54","first-page":"8369","article-title":"Pharmacokinetics changes of ivabradine and N-desmethylivabradine after oral administration with puerarin in rats","volume":"9","author":"Zhang","year":"2016","journal-title":"Int J Clin Exp Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:54:43Z","timestamp":1740675283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0022356524270658"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000348","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Integrative Approach for Improved Assessment of Cardiovascular Safety Data","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}